# AMBASSADOR (NCT03244384)

> Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03244384
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Localized Renal Pelvis and Ureter Urothelial Carcinoma; Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage II Renal Pelvis and Ureter Cancer AJCC v7; Stage II Ureter Cancer AJCC v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Renal Pelvis and Ureter Cancer AJCC v7; Stage III Ureter Cancer AJCC v7
- Interventions: Biospecimen Collection; Clinical Observation; Computed Tomography; CT Urography; Cystoscopy; Magnetic Resonance Imaging; Pembrolizumab; Pharmacological Study; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 739
- Primary outcome: Overall survival
- Primary outcome: Disease-free survival

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ambassador-nct03244384